Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
AssigneeMemorial Sloan Kettering Cancer Center
InventorsRaymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Claims64
A method for treating acute promyelogenous leukemia in a human comprising administering 0.15 mg/kg arsenic trioxide once per day.
A method for treating acute myelogenous leukemia in a human, comprising:
- determining a therapeutically effective dosage of arsenic trioxide based on i) the weight of a subject diagnosed with acute myelogenous leukemia and (ii a dosage amount of 0.15 mg/kg;
- and
- administering the therapeutically effective dosage of arsenic trioxide once per day.
A method for treating acute promyelogenous leukemia, comprising determining a dosage amount of arsenic trioxide for the treatment of a patient diagnosed with acute promyelogenous leukemia, based on the weight of the patient and a dose of 0.15 mg/kg of patient body weight, and administering arsenic trioxide in said dosage amount to said patient.
Dependencies are inferred from the claim text.